minigene

minigene

A popular term for a gene segment which encodes a variable region of either a heavy or light chain of an immunoglobulin.

minigene

a GENE that has been cloned and subjected to DELETION, by in vitro MUTAGENESIS, to reduce its size.
References in periodicals archive ?
Control mice receiving vectors lacking the ZFNs or the F9 minigene had no significant improvements in circulating factor or in clotting times.
The SOD2-knockout allele was screened by targeting amplification of the hprt minigene used to generate the knockout by using HPRTxl-2F (5'-CAGCCCTGGCGTCGTGAT TAGT-3') and HPRTx7R (5'-CGTGGGGTCCTTTTCACCAGCAA-3'), yielding a 2.
The use of gene therapy is to inject a smaller yet functional version of the gene - called a minigene - within the viral carrier.
A Multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen.
The majority of these used reverse transcriptase PCR (RT-PCR) [27] analysis of RNA extracted from blood of variant carriers or alternatively, minigene constructs containing the variant and assayed in non-patient-derived cell lines.
Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
in San Diego, California where he pursued pre-clinical development of several infectious disease vaccines, using the company's DNA vaccine minigene technology.
Knockout mice had been generated by removing portions of exons 2 and all of exons 3-5 of the Cyp1a2 gene; insertion of the Hprt minigene cassette was used for selection in embryonic stem (ES) cell cultures (Liang et al.
The >5-fold elevation in Hprt gene expression (Table 1) is likely explained by the Hprt minigene cassette used in the selective elimination to disrupt the Cyp1a2 (Liang et al.
To confirm these in silico predictions we performed minigene expression studies.
Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites.